Robin Roberts, Breast Cancer, and 'Making Your Mess Your Message'

A lump found on an ordinary night

Robin Roberts told her audience about her breast cancer on July 31, 2007. She had found the lump herself, and she said the timing was not random.

"That very night when I went to bed, I did a self breast exam and found something that women everywhere fear: I found a lump," she wrote. She had just learned that her ABC colleague Joel Siegel had died of cancer. Her announcement opened simply: "I never thought I'd be writing this. … I have breast cancer."

ABC News reported that she had surgery on August 3, 2007, and that she expected follow-up treatment in the months ahead. That is the extent of what she made public at the time, and it is the extent of what belongs here about her. The rest of this page is about the disease.

What the pathology report is actually measuring

Breast cancer begins when cells in the breast grow out of control. Most start in the ducts, the thin tubes that carry milk toward the nipple, though some start in the lobules, the glands that make milk.

Diagnosis usually runs through a short sequence. The National Cancer Institute's clinician guidance lists it as "Mammography. Ultrasonography. Breast magnetic resonance imaging (MRI), if clinically indicated. Biopsy." Only the biopsy, which removes a sample of tissue, settles the question.

Staging then uses the AJCC TNM system, which records tumor size, whether lymph nodes are involved, and whether the cancer has spread to distant organs. Doctors often check the sentinel node first, meaning the lymph node the tumor is most likely to drain into.

Three tests that steer everything after that

Two tumors that look identical on a scan can call for completely different drugs. NCI lists the features that drive that choice: "Menopausal status of the patient. Stage of the disease. Grade of the primary tumor. Estrogen receptor (ER) and progesterone receptor (PR) status of the tumor. Human epidermal growth factor type 2 receptor (HER2) overexpression and/or amplification."

Receptors are docking sites on the cancer cell. NCI explains that ER is measured mainly by immunohistochemistry, a stain applied to the tissue, and that "any staining of 1% of cells or more is considered positive for ER." Progesterone receptors use the same cutoff. A hormone receptor positive cancer can often be treated with hormone therapy, which blocks or lowers estrogen.

HER2 is a growth-signaling protein. NCI says it is measured "either by IHC to assess expression of the HER2 protein or by in situ hybridization (ISH) to assess gene copy number." HER2 positive cancers respond to drugs built specifically against that target.

Ask for these three results by name. They are the difference between one treatment plan and another.

When to get checked

CDC names these as warning signs. Any of them deserves an appointment, and none of them should be watched for months.

• A new lump in the breast or in the armpit
• Thickening or swelling of part of the breast
• Skin that is dimpled, irritated, red, or flaky over the breast or nipple
• A nipple that starts pulling inward, or pain in the nipple area
• Any nipple discharge other than breast milk, including blood
• A change in the size or shape of one breast
• Pain anywhere in the breast that does not come and go with your cycle

CDC adds that these signs happen with non-cancerous conditions too. That is a reason to get checked, not a reason to wait.

Screening is a schedule, not a symptom

CDC states the U.S. Preventive Services Task Force recommendation directly: women 40 to 74 years old at average risk should get a mammogram every two years. CDC also notes that different schedules may apply to women at higher than average risk.

Higher risk includes a strong family history and certain inherited gene changes. If either applies to you, that conversation should happen well before age 40.

What treatment involves

NCI's summary is compact: "Breast cancer is commonly treated by various combinations of surgery, radiation therapy, chemotherapy, and hormone therapy."

Surgery may be breast conserving, sometimes called a lumpectomy, or a mastectomy that removes the whole breast. Breast conserving surgery is usually paired with radiation therapy. Systemic treatment, meaning drugs that travel through the bloodstream, is chosen from the receptor results. Hormone therapy for ER positive disease often runs for five years or longer, which is a commitment worth understanding before it starts.

What the survival numbers cover

The American Cancer Society projected 321,910 new cases of female breast cancer and 42,140 deaths in the United States for 2026, and SEER, NCI's cancer surveillance program, publishes those projections. The rate of new cases is 132.5 per 100,000 women per year, and the median age at diagnosis is 64.

Five-year relative survival across all stages is 91.9 percent, based on cases from 2016 through 2022. Relative survival compares people with the diagnosis to people of the same age without it. Broken out by stage, SEER lists 100.0 percent for localized disease, 87.5 percent when nearby lymph nodes are involved, and 33.8 percent when the cancer has reached distant organs.

Stage distribution is why screening keeps coming up. For that same 2016 to 2022 group, SEER records 64 percent of cases as localized at diagnosis and 6 percent as distant. These are averages across a very large group, and no individual reader is described by them.

Her second diagnosis, and why it belongs here

On June 11, 2012, Roberts told viewers she had myelodysplastic syndrome. She described it as "a disease of the blood and bone marrow and was once known as preleukemia," and she said plainly: "Sometimes the treatment for cancer can cause other serious medical problems." She went on to have a bone marrow transplant.

NCI confirms the general pattern she was describing. Myelodysplastic syndromes "may arise de novo or secondarily after treatment with chemotherapy and/or radiation therapy for other cancers." Common early findings are anemia, bleeding, easy bruising, and fatigue. NCI states that an allogeneic transplant, using donor stem cells, "is the only potentially curative treatment for MDS."

This is rare, and it is not a reason to refuse treatment. It is a reason to keep a written record of every drug and radiation field you received, and to stay in follow-up long after the last appointment feels necessary.

Sources

• https://abcnews.com/GMA/CancerPreventionAndTreatment/abcs-robin-roberts-breast-cancer/story?id=3430554
• https://www.goodmorningamerica.com/wellness/story/robin-roberts-myelodysplastic-syndrome-diagnosis-beat-16540293
• https://www.cancer.gov/types/breast/hp/breast-treatment-pdq
• https://www.cancer.gov/types/myeloproliferative/hp/myelodysplastic-treatment-pdq
• https://seer.cancer.gov/statfacts/html/breast.html
• https://www.cdc.gov/breast-cancer/symptoms/index.html
• https://www.cdc.gov/breast-cancer/screening/index.html